# (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

> **NCT04862780** · PHASE1 · TERMINATED · sponsor: **Blueprint Medicines Corporation** · enrollment: 177 (actual)

## Conditions studied

- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Respiratory Tract Neoplasms
- Neoplasms
- Neoplasms by Site
- Lung Diseases
- Respiratory Tract Disease
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Adenocarcinoma
- Carcinoma
- Neoplasms by Histologic Type
- Neoplasms, Nerve Tissue
- EGFR T790M
- EGFR C797S
- EGFR L858R
- EGFR Gene Mutation
- EGF-R Positive Non-Small Cell Lung Cancer
- EGFR Exon 19 Deletion
- EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance
- EGFR Activating Mutation
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Thoracic Neoplasms

## Interventions

- **DRUG:** BLU-945
- **DRUG:** osimertinib

## Key facts

- **NCT ID:** NCT04862780
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-29
- **Primary completion:** 2024-10-07
- **Final completion:** 2024-10-07
- **Target enrollment:** 177 (ACTUAL)
- **Why stopped:** Sponsor decision, not related to safety concerns
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04862780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04862780, "(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04862780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*